ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
24 announcements
Colinz Laboratories held its 40th Annual General Meeting on September 22, 2026, where shareholders considered financial statements and director appointments.
Colinz Laboratories Ltd issued a Post Offer Advertisement for an Open Offer. The offer closed with only 6 shares tendered out of a proposed 6,54,966 shares.
Colinz Laboratories Limited has submitted its 40th Annual Report for the financial year 2025-26. The report includes notice for the Annual General Meeting scheduled for September 22, 2026.
Colinz Laboratories Ltd has issued the notice for its 40th Annual General Meeting scheduled for September 22, 2026. The agenda includes director re-appointments and auditor report adoption.
Saffron Capital Advisors filed a reminder advertisement for the open offer of Colinz Laboratories. The offer seeks to acquire up to 26% stake for ₹3.54 Crore.
The acquirers made an Open Offer to buy up to 6,54,966 shares of Colinz Laboratories Limited at ₹54 per share. This offer totals ₹3.54 Crore.
Colinz Laboratories Ltd reported revenue from operations of ₹1.2 Cr (-25.0% YoY) and net profit of ₹2.4 Cr (+2300.0% YoY) for Q1 FY27.
Colinz Laboratories has scheduled a board meeting for July 30, 2026, to consider quarterly financial results and other corporate matters.
Colinz Laboratories faces a mandatory open offer for 26% of its shares. The offer, valued at Rs.3.54 Crore, is led by Saffron Capital Advisors on behalf of the acquirers.
Colinz Laboratories Ltd states related party transaction disclosures are exempt for Q2 2026 under SEBI LODR 23(9). The filing complies with exemption under Regulation 15(2)(a).
Colinz Laboratories completed the sale of its factory and land to Hilsun Foods. The total consideration received for the transaction is ₹4 Crore.
Anajuna Duggar and others launched an open offer for Colinz Laboratories Ltd. The offer aims to acquire 26% stake at Rs. 54 per share.
Colinz Laboratories responded to a BSE query on share price movement, stating no UPSI exists. The price move is attributed to market conditions, not company actions.
Mr. Padam Dugar and PACs acquired a 15.01% stake in Colinz Laboratories through an off-market transaction. This significant non-promoter entry impacts the company's shareholding structure.
Padam Dugar and associates acquired a 15.01% stake in Colinz Laboratories through an off-market transaction. This significant acquisition increases their total holding to 3,78,000 shares.
Promoter Vijaya Mani sold 3,78,000 shares of Colinz Laboratories via an off-market transaction. The sale reduced the promoter's stake from 49.56% to 34.56%.
Colinz Laboratories Ltd reported revenue from operations of ₹1.7 Cr (+13.3% YoY) and net profit of ₹0.2 Cr (+0.0% YoY) for Q4 FY26.
Colinz Laboratories Ltd approved its audited financial results for the year ended March 31, 2026. The company reported a total income of ₹6.62 Crore and a net profit of ₹0.51 Crore for the fiscal year. The board confirmed the results were prepared in accordance with Indian Accounting Standards (IND-AS).
Colinz Laboratories Ltd submitted its Integrated Filing (Financial) for the quarter and year ended March 31, 2026. The submission includes financial results and statements regarding deviations and related party transactions as per SEBI requirements.
Colinz Laboratories Ltd has scheduled a Board Meeting on April 29, 2026, to approve audited financial results for the quarter and year ended March 31, 2026. Consequently, the trading window for dealing in company securities remains closed from April 1, 2026, until 48 hours after the results declaration.
Colinz Laboratories Ltd reported net profit of ₹0.1 Cr (+0.0% YoY) for Q3 FY26.
Colinz Laboratories Ltd submitted a declaration to BSE confirming that Regulation 32 regarding Statements of Deviation or Variation is not applicable for Q4 FY2026. The company stated it did not undertake any public, rights, preferential issues, or QIPs during the quarter, indicating no deviation in fund utilisation.
Colinz Laboratories Ltd has filed a declaration stating that Related Party Transaction disclosures under Regulation 23(9) are not applicable for the quarter ended March 31, 2026. The company is claiming exemption under Regulation 15(2)(a) of SEBI (LODR) Regulations, 2015. This is a routine regulatory compliance update.
Colinz Laboratories Ltd confirmed it is not identified as a Large Corporate for the financial year ended March 31, 2026. Consequently, the company is not required to file initial or annual disclosures under the SEBI framework for fund raising by issuance of debt securities.